Search results
Showing 8281 to 8295 of 8796 results
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Discontinued Reference number: GID-TA10694
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]
Discontinued Reference number: GID-TA11647
Nitazoxanide for treating the common cold in people 12 years and over [ID4049]
Discontinued Reference number: GID-TA11128
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
Discontinued Reference number: GID-TA11228
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Discontinued Reference number: GID-TA11086
Discontinued Reference number: GID-TA11338
In development Reference number: GID-TA11457 Expected publication date: TBC
This guideline has been updated and replaced by NICE guideline NG257.
Palforzia for treating peanut allergy in children and young people (TA769)
NICE has withdrawn this guidance. This is because Stallergenes Greer have discontinued the Palforzia initial dose escalation pack. No new people will start taking Palforzia in the UK. Healthcare professionals should discuss alternative treatment options. People currently having Palforzia will be able to continue until March 2027.
In development Reference number: GID-TA11586 Expected publication date: TBC
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]
Discontinued Reference number: GID-TA10199
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development Reference number: GID-HST10037 Expected publication date: TBC
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain
In development Reference number: GID-MT567 Expected publication date: TBC
In development Reference number: GID-TA10261 Expected publication date: TBC
In development Reference number: GID-TA11679 Expected publication date: TBC